Loading...
Loading...
Analysts at KeyBanc downgraded DaVita HealthCare Partners
DVA from Buy to Hold and removed the target price of $75.
DaVita shares have jumped 26.58% over the past 52 weeks, while the S&P 500 index has surged 15.85% in the same period.
DaVita's shares rose 0.42% to close at $74.24 yesterday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
